Aryna Sabalenka didn’t dodge the question. Speaking at a press conference ahead of the Canadian Open in Montreal on August 4, 2026, the world No. 1 and four-time Grand Slam champion came out in support of the WTA’s new mandatory genetic sex testing policy, calling it ‘really important to keep the fairness in our tour.’ The statement landed in a debate that is very much alive — even though, right now, there is no trans woman competing anywhere on the WTA circuit.
What the WTA’s New Policy Actually Says
The WTA announced its new eligibility rule on July 21, 2026, and it is a significant departure from what came before. Under the previous 2024 policy, trans women could compete in the women’s draw if they maintained testosterone levels below 2.5 nmol/L for at least two continuous years — a hormonal threshold approach that many sports governing bodies had been using. The new rule replaces that entirely: every player must now undergo a one-time genetic test to detect the presence of the SRY gene, located on the Y chromosome and associated with the development of male biological characteristics. The test can be done via cheek swab, blood, or saliva sample.
One detail that drew attention from legal analysts: the new policy is governed by the laws of the state of Florida, a notable shift from the 2024 policy which operated under New York law. The WTA is widely cited as the first professional women’s tennis organization to implement this kind of genetic test — though World Boxing adopted the SRY test back in May 2025, making women’s tennis a follower rather than a pioneer in this specific testing method. The International Olympic Committee had also moved in a similar direction before the WTA announcement.
Sabalenka’s Words and Why They Carry Weight
When Sabalenka speaks, the tour listens. At 28 years old, the Belarusian from Minsk is not just ranked number one — she has won four Grand Slams in three seasons: the Australian Open in 2023 and 2024, and the US Open in 2024 and 2025. Through the first half of 2026, she holds a 27-3 record and three titles. That résumé makes her declaration meaningful in a way that a lower-ranked player’s wouldn’t be.
What she said was direct, not inflammatory. ‘Biologically, men are much stronger than women,’ she told reporters in Montreal, adding that she believes the genetic test is a fair mechanism for protecting competitive equity. She didn’t name anyone, didn’t call out any individual, and didn’t stray beyond the institutional question. But the political timing was hard to miss: President Donald Trump had already signed an executive order on transgender athletes ahead of the 2028 Los Angeles Olympics, and the U.S. Supreme Court had upheld state-level bans preventing trans athletes from competing in female categories at the high school and college level. Sabalenka stepped into that current, deliberately or not.
The comparison that keeps surfacing is WNBA player Sophie Cunningham, who voiced similar views and was booed at games — a reminder that elite athletes who take this stance absorb real reputational cost. Sabalenka, for her part, showed no sign of backing down.
The Irony That Keeps the Debate Honest
Here is the part that complicates the easy narrative on both sides: as of August 2026, there is no known trans woman competing anywhere on the WTA tour. The policy is, by design, preventive. That raises a legitimate question about whether the urgency matches the reality — and it is precisely what critics, including LGBTQ+ advocacy groups, have pointed to in calling the measure discriminatory.
The historical irony is not lost on anyone paying attention. The WTA was founded in 1973 by Billie Jean King, one of the most prominent LGBTQ+ rights advocates in the history of professional sport and a vocal supporter of trans inclusion in athletics. That the organization she built now requires genetic testing to determine eligibility is, at minimum, a striking institutional pivot.
None of this means Sabalenka’s position is without logic. Competitive equity in elite women’s sport is a real concern, and her framing stayed within those bounds. But the gap between the policy’s scope and the current reality on tour is wide enough to keep this conversation from being simple — which is probably why it is still moving so fast.
